immune checkpoint inhibitors or docetaxel

This entry refers to a combination therapy approach using either immune checkpoint inhibitors (ICIs) or the chemotherapeutic agent docetaxel, both of which are used in cancer treatment. Immune checkpoint inhibitors are monoclonal antibodies that target inhibitory receptors on T-lymphocytes, such as PD-1, PD-L1, and CTLA-4. By blocking these checkpoints, ICIs reinvigorate the host immune system to recognize and attack tumor cells[1][3][4]. Commonly approved ICIs include nivolumab, pembrolizumab (PD-1 inhibitors), atezolizumab (PD-L1 inhibitor), and ipilimumab (CTLA-4 inhibitor)[1]. Docetaxel is a second-generation taxane chemotherapeutic that binds β-tubulin in microtubules, stabilizing them and preventing their depolymerization. This disrupts mitotic spindle formation during cell division, leading to cell cycle arrest at G2/M phase and promoting apoptosis by downregulating anti-apoptotic proteins like BCL2[2][6][8][10]. Both modalities are widely used for various cancers including non-small cell lung cancer (NSCLC) and prostate cancer; clinical studies have shown that ICIs can improve survival outcomes compared to docetaxel in certain settings[3][4].

Other names

ICIs or docetaxelimmune checkpoint inhibitors and/or docetaxel